多器官转移性结直肠癌减瘤联合化疗的ORCHESTRA随机临床试验
这项多中心随机临床试验纳入382例多器官转移性结直肠癌患者,在化疗达到疾病控制后随机接受单纯化疗或减瘤术后化疗。
要点
- 在多器官转移性结直肠癌中,一线化疗基础上联合减瘤未能改善总生存。
- 减瘤联合化疗组严重不良事件发生率显著高于单纯化疗组。
- 研究结论不支持将减瘤作为该人群的标准治疗。
核心结论
- 在化疗达到客观缓解或疾病稳定后,联合减瘤未能改善多器官转移性结直肠癌患者的总生存。
- 与单纯化疗相比,减瘤联合化疗的严重不良事件更多,不推荐作为标准治疗。
研究设计与样本
- 研究者发起的开放标签多中心随机临床试验,2013年5月至2023年5月入组,末次随访2024年4月4日。
- 在荷兰27家医院和英国1家医院入组多器官转移性结直肠癌成人患者。
- 454例入组患者中382例随机:单纯化疗组192例,化疗联合减瘤组190例;两组中位年龄均为64岁。
- 入组条件为一线姑息化疗前评估可通过切除、放疗和/或热消融实现超过80%肿瘤减瘤。
- 随机前需接受3周期卡培他滨联合奥沙利铂或4周期5-氟尿嘧啶联合奥沙利铂(可联合贝伐珠单抗)后达到客观缓解或疾病稳定。
临床怎么用
- 多器官转移性结直肠癌患者一线化疗后不常规推荐联合减瘤治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Local therapy, including surgery, radiation, and ablation, is increasingly used in patients with multiorgan metastatic colorectal cancer (mCRC). However, prospective evidence for a survival benefit of tumor debulking is lacking. OBJECTIVE: To investigate whether tumor debulking added to palliative chemotherapy improves survival of patients with multiorgan mCRC. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, open-label, multicenter, randomized clinical trial enrolled patients with multiorgan mCRC between May 2013 and May 2023. The last date of follow-up was April 4, 2024. Patients were enrolled in 27 hospitals in the Netherlands and 1 in the UK. Adult patients with multiorgan mCRC were considered eligible if more than 80% tumor debulking was deemed feasible by resection, radiotherapy, and/or thermal ablation prior to starting first-line palliative chemotherapy. INTERVENTIONS: After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without bevacizumab, patients were randomized 1:1 to receive chemotherapy alone (standard care group) or tumor debulking followed by chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. Secondary end points included progression-free survival and serious adverse events. These outcomes were analyzed in the intention-to-treat population, applicable from randomization. A prespecified interim analysis performed after the initial 100 participants were enrolled revealed that the trial was both safe and feasible to proceed. RESULTS: A total of 382 of 454 enrolled patients were randomized: 192 in the chemotherapy alone group (133 [69%] male) and 190 in the chemotherapy plus tumor debulking group (127 [67%] male). The median age was 64 years in both groups. After a median follow-up of 32.3 months, median overall survival in the chemotherapy alone group was 27.5 months vs 30.0 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.88 [95% CI, 0.70-1.10]; P = .26). Median progression-free survival in the chemotherapy alone group was 10.4 months vs 10.5 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.83 [95% CI, 0.67-1.02]; P = .08). More patients in the chemotherapy plus tumor debulking vs chemotherapy alone group had any serious adverse events (101 [53%] vs 74 [39%]; P = .006). CONCLUSIONS AND RELEVANCE: Tumor debulking in addition to first-line palliative systemic treatment failed to improve overall survival compared with systemic treatment alone for patients with multiorgan mCRC and should not be considered standard care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01792934.
引用
- Gootjes EC, Bakkerus L, Adhin AA, et al. Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial. JAMA. 2026. PMID: 41837962. doi:10.1001/jama.2026.1929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。